Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;13(3):281-7.
doi: 10.2174/1567205013666151218150322.

Defining the earliest pathological changes of Alzheimer's disease

Affiliations
Review

Defining the earliest pathological changes of Alzheimer's disease

James C Vickers et al. Curr Alzheimer Res. 2016.

Abstract

The prospects for effectively treating well-established dementia, such as Alzheimer's disease (AD), are slim, due to the destruction of key brain pathways that underlie higher cognitive function. There has been a substantial shift in the field towards detecting conditions such as AD in their earliest stages, which would allow preventative or therapeutic approaches to substantially reduce risk and/or slow the progression of disease. AD is characterized by hallmark pathological changes such as extracellular Aβ plaques and intracellular neurofibrillary pathology, which selectively affect specific subclasses of neurons and brain circuits. Current evidence indicates that Aβ plaques begin to form many years before overt dementia, a gradual and progressive pathology which offers a potential target for early intervention. Early Aβ changes in the brain result in localized damage to dendrites, axonal processes and synapses, to which excitatory synapses and the processes of projection neurons are highly vulnerable. Aβ pathology is replicated in a range of transgenic models overexpressing mutant human familial AD genes (e.g. APP and presenilin 1). Studying the development of aberrant regenerative and degenerative changes in neuritic processes associated with Aβ plaques may represent the best opportunity to understand the relationship between the pathological hallmarks of AD and neuronal damage, and to develop early interventions to prevent, slow down or mitigate against Aβ pathology and/or the neuronal alterations that leads to cognitive impairment.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Diagram indicating the range of alterations associated with neuritic plaque formation. These include clipping and deflection of dendrites, loss of spines, axons and synapses. Four dystrophic neurite isoforms are present – those predominantly containing either NFs or altered tau, and a further group containing NFs with a core of pathological tau. Another group of dystrophic neurites are characterized by the presence of synaptic markers.

References

    1. Vickers J.C., King A.E., Woodhouse A., Kirkcaldie M.T., Staal J.A., McCormack G.H., et al. Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. Brain Res. Bull. 2010;80:217–223. - PubMed
    1. Rogers J., Morrison J.H. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer’s disease. J. Neurosci. 1985;5:2801–2808. - PMC - PubMed
    1. Fiala J.C. Mechanisms of amyloid plaque pathogenesis. Acta Neuropathol. 2007;114:551–571. - PubMed
    1. Dickson T.C., Vickers J.C. The morphological phenotype of β-amyloid plaques and associated neuritic changes in Alzheimer’s disease. Neuroscience. 2001;105:99–107. - PubMed
    1. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkaine A., et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature. 2008;451:720–724. - PMC - PubMed

Publication types

Substances